Key result
Combined ECG-echocardiographic indices differentiate cardiac amyloidosis from phenocopies with ~83% accuracy.
Why the study?
Distinguishing sarcomeric hypertrophic cardiomyopathy from Fabry disease and cardiac amyloidosis remains a diagnostic challenge due to overlapping left ventricular wall thickening, prompting an evaluation of the diagnostic utility of ECG alone and combined with echocardiography.
Does electrocardiography, alone and combined with echocardiography, improve diagnostic differentiation in patients with hypertrophic cardiomyopathy, Fabry disease, and cardiac amyloidosis?
Does electrocardiography, alone and combined with echocardiography, improve diagnostic differentiation in patients with hypertrophic cardiomyopathy, Fabry disease, and cardiac amyloidosis?
ECG parameters, both standalone and integrated with echocardiographic indices like left ventricular mass and wall thickness, provide high diagnostic accuracy for differentiating sarcomeric hypertrophic cardiomyopathy from its phenocopies, Fabry disease and cardiac amyloidosis.
Answers are grounded in this paper and cite their sources.
ECG-integrated QRS/LVMI indices may aid differentiation of cardiac amyloidosis from HCM and Fabry disease; leaves open prospective validation before clinical adoption.
Introduction Distinguishing sarcomeric hypertrophic cardiomyopathy (HCM) from Fabry disease and cardiac amyloidosis remains a diagnostic challenge due to their overlapping structural manifestations. Despite similar left ventricular wall thickening, differences in myocardial architecture and electrical remodeling may provide valuable etiological clues. This review evaluates the diagnostic utility of electrocardiography (ECG), alone and combined with echocardiography, in differentiating these conditions. Materials and methods PubMed was searched on October 28, 2026, for publications from 2021 to 2026 using terms related to hypertrophic cardiomyopathy, Fabry disease, cardiac amyloidosis, electrocardiography, and echocardiography. Of the 102 records identified, 15 publications were selected following screening for relevant ECG abnormalities, diagnostic discrimination, or integrated ECG-echocardiographic indices. Animal and in vitro studies, treatment-only publications, and studies lacking relevant diagnostic data were excluded. Results In a cohort of 222 patients, a five-parameter ECG score incorporating PR shortening, QRS prolongation, right bundle branch block, increased R-wave amplitude in aVL, and inferior ST depression differentiated Fabry disease from HCM with a c-statistic of 0.80 (95% CI 0.74-0.86), 69% sensitivity, and 84% specificity. In cardiac amyloidosis, the ECG voltage-to-left ventricular mass ratio demonstrated an AUC of 0.90 (95% CI 0.874-0.927), with 89.0% sensitivity and 80.8% specificity against combined comparison groups. In a multicenter cohort involving 1,181 patients, the total QRS score/left ventricular mass index (cutoff < 0.695) distinguished cardiac amyloidosis from HCM and Fabry disease with 82.9% accuracy (95% CI 80.62-85.02), 62.4% sensitivity (95% CI 57.45-67.18), and 93.6% specificity (95% CI 91.62-95.22), with an AUC of 0.898 (95% CI 0.880-0.917). The total QRS score/maximum left ventricular wall thickness ratio differed significantly among all three conditions (p < 0.001). Conclusion Beyond shared morphological features, ECG patterns may offer valuable clues to the underlying etiology of left ventricular hypertrophy. Although current evidence is limited by retrospective designs and insufficient external validation, these findings support further investigation into their clinical applicability.
No takes yet. Share an insight, caveat, or question.
Agapi et al. (2026) conducted a review in Hypertrophic cardiomyopathy, Fabry disease, and cardiac amyloidosis. Electrocardiography (ECG) alone and combined with echocardiography was evaluated on Diagnostic differentiation between sarcomeric hypertrophic cardiomyopathy, Fabry disease, and cardiac amyloidosis (AUC 0.898, 95% CI 0.880-0.917, p=<0.001). Integrated ECG-echocardiographic indices like total QRS score/LV mass index distinguished cardiac amyloidosis from HCM and Fabry disease with 82.9% accuracy.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: